Vir Biotechnology announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer, CEO, effective April 3, 2023. The Company’s Board of Directors has appointed industry veteran Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals Strategy, Business Development and Licensing/Open Innovation, and Member of the Executive Committee for Bayer Pharmaceuticals, as his successor, effective April 3, 2023. She will also join Vir‘s Board of Directors. Upon his retirement as CEO, Dr. Scangos will serve in an advisory role to Dr. De Backer through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VIR:
- Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
- Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
- Vir Biotechnology achieves target enrollment for Phase 2 PENINSULA trial
